United Biotechnology (The United Bio-Technology (Hengqin) Co., Ltd.) is a biopharmaceutical R&D subsidiary of The United Laboratories International Holdings Limited (TUL). The company develops innovative candidates including UBT251 and serves as TUL’s biopharmaceutical R&D headquarters in Hengqin, China. It has entered global licensing activities through collaborations announced with Novo Nordisk.
Novo Nordisk and China's United Biotechnology reported that experimental obesity drug UBT251 led to mean weight loss of up to 19.7% in a midstage clinical trial in China, expanding Novo's obesity pipeline.
Novo Nordisk's experimental triple-action obesity drug UBT251 achieved up to 19.7% weight loss in a Phase 2 trial in China, as the company works to regain ground against rival Eli Lilly in the obesity drug market.
